CClinicalTrials.gg
CompletedNCT05106803Updated Nov 4, 2021

Antibiotic Profile of Pathogenic Bacteria Isolated in Public Hospitals in Northern Jordan

An observational study in Bacterial Infections, Antibiotic Resistant Infection and Surgical Site Infection, sponsored by Yarmouk University. Completed at 1 site in Jordan. Per ClinicalTrials.gov, last updated 2021-11-04.

Sponsored by Yarmouk University · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
24
Sex
All
01

Study summary

The main aim of the study was to identify the various pathogens associated with surgical site infections and their antibiotic susceptibility in a governmental hospital in northern Jordan.

Read the detailed description

Background: Surgical site infections are hospital-acquired, vary from one hospital to another, and can cause significant postoperative morbidity, mortality, and prolonged hospital stay.

Aim: The main aim of the study was to identify the various pathogens associated with surgical site infections and their antibiotic susceptibility in a governmental hospital in northern Jordan.

Methods: Postsurgical wound samples were collected and processed in a microbiology laboratory using standard microbiological techniques. Antibiotic susceptibility tests were performed using 13 antibiotics covering the gram-positive and gram-negative bacteria using the disc diffusion test.

02

Conditions studied

  • Bacterial Infections
  • Antibiotic Resistant Infection
  • Surgical Site Infection

Keywords

  • antimicrobial
  • hospital
  • post-surgical infection
  • surgery
03

In context

Infections

6,687 studies on the registry are indexed under Infections; 807 are open to participants now.

This study's enrollment of 24 is below the median of 240 across 2,136 observational studies indexed under Infections.

Browse Infections studies →

Lead sponsor

Yarmouk University is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Sampling method
Probability sample

Study population

A hospital-based prospective study was carried out in Public-Teaching Hospital in northern Jordan with a total capacity of 400 beds, All patients meet the criteria of getting post-operative wound infections in different surgical wards and ICUs.

Inclusion criteria

  • Post-Surgical Wound Infection

Exclusion criteria

Exclusion Criteria:

-

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
24 participants (actual)
Patient registry
No

Groups and cohorts

  • Wound infection

    Patients with surgical site infection as diagnosed by the attending physician

    Drug: ciprofloxacin

Interventions

  • Drugciprofloxacin

    Antibiotics used in vitro n the study

    Also known as: trimethoprim-sulfamethoxazole, norfloxacin, erythromycin, chloramphenicol, gentamicin, tetracycline, vancomycin, amoxicillin/clavulanic acid, cefepime, penicillin, ampicillin, clindamycin, oxacillin

06

What researchers measure

Primary outcomes

  1. Positive culture

    Positive swab culture from the wound

    Time frame: August 2019 to October 2019

Secondary outcomes

  1. Gram stain and type of Bacteria

    Gram stain and type of Bacteria grown in culture media

    Time frame: August 2019 to October 2019

  2. Antibiotic Susceptibility

    Antibiotic Susceptibility to the isolated organisms

    Time frame: August 2019 to October 2019

07

Study locations

1 site
  • Yarmouk University
    Irbid, 21163, Jordan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 4, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05106803
Lead sponsor
Yarmouk University
Responsible party
Raed M Ennab (Assistant Professor, Yarmouk University) — Principal investigator
First posted
Nov 4, 2021
Start date
Aug 1, 2019
Primary completion
Oct 1, 2019
Completion
Oct 1, 2019
Last update
Nov 4, 2021

Study contacts

Raed M Ennab
principal investigator · Department of Clinical Sciences, Faculty Of Medicine, Yarmouk University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion